GSK announces positive results from phase III severe asthma trials …
May 21, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of …
Depemokimab accepted for review by the European Medicines Agency ... - GSK
Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5), is the first ultra-long-acting biologic to be evaluated in phase III trials and be accepted for regulatory review for use in …
GSK announces positive phase III results from ANCHOR trials for ...
Oct 14, 2024 · Depemokimab’s extended half-life, high potency and high binding affinity for IL-5 means it has the potential to provide sustained inhibition of broad inflammatory functions with …
Depemokimab applications accepted for review in China and …
2 days ago · Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5), is the first ultra-long-acting biologic to be evaluated in phase III trials and be accepted for regulatory …
GSK’s twice-yearly asthma drug clears two phase 3 trials
5 days ago · The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly …
Twice-Yearly Depemokimab in Severe Asthma with an …
Sep 9, 2024 · Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, …
GSK boasts win for depemokimab in asthma trials - Clinical Trials …
May 21, 2024 · GSK has announced positive data from two Phase III trials of its asthma candidate depemokimab. The pharma giant announced the drug met primary endpoints in both the …
Phase III Trials Show Depemokimab Reduces Severe Asthma …
Jun 12, 2024 · In addition to SWIFT-1 and SWIFT-2, GSK is conducting the NIMBLE study, which evaluates the efficacy and safety of depemokimab in patients transitioning from other IL-5 …
GSK to Approach FDA With Positive Phase III Data For Long
Sep 9, 2024 · GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it for an estimated $4 billion in peak sales if approved.
GSK's long-acting asthma drug halved attacks in phase 3
Sep 9, 2024 · GSK is continuing to tout depemokimab as one of its 12 potential blockbuster launches of the coming years, with the asthma drug expected to generate peak-year sales of 3 …